RECCE PHARMACEUTICALS LTD — Board/Management Information 2020

Sep 29, 2020

ASX Announcement

==> picture [416 x 93] intentionally omitted <==

Recce Pharmaceuticals Appoints Michele Dilizia as Chief Scientific Officer

Sydney Australia, 30 September 2020: Recce Pharmaceuticals Ltd ( ASX: RCE ), the Company developing New Classes of Synthetic Anti-infectives, is pleased to announce the Board of Directors has unanimously appointed Michele Dilizia to the role of Chief Scientific Officer. Ms Dilizia will also continue her role as Executive Director and as member of the Board of Directors.

Recce Pharmaceuticals Non-Executive Chairman Dr John Prendergast said, “As Co-Inventor of Recce’s Synthetic Anti-Infectives, Michele’s significant contributions to the Company reflects her strong scientific acumen and deep expertise in synthetic anti-infectives. Michele has demonstrated leadership and expertise that has been instrumental to the development of RECCE[®] compounds. As Michele takes on her new role, the Board is confident in her ability to continue advancing the Company’s clinical initiatives.”

Ms Dilizia’s specilisation is in medical microbiology and regulatory affairs. Michele successfully co-led the research and development of Recce’s suite of anti-infective compounds, resulting in a portfolio of granted patents across the globe, including a Qualified Infectious Disease Product designation with the FDA.

Chief Scientific Officer Michele Dilizia said, “I am delighted to have been appointed this role by the Board and it has been my privilege to contribute to the development of a unique technology like RECCE[®] Anti-Infectives. I look forward to continue working with the research team to build on the Company’s anti-infective pipeline in the pursuit to unlock the full clinical potential of our technology in the time ahead.”

Ms Dilizia will deliver the Opening R&D Address at the World Anti-Microbial Resistant (AMR) Congress in the coming week, where she will present ‘ Synthetic Antibiotics: The New Approach the World Needs ’ to be centred around Recce’s leading anti-infective pipeline in the space.

The key terms and conditions of Ms Dilizia’s appointment are set out in Attachment 1

==> picture [595 x 57] intentionally omitted <==

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE[®] 327 and RECCE[®] 435, and RECCE[®] 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Recce’s new antibiotic compound, RECCE[®] 435, has been formulated for oral use.

The FDA has awarded RECCE[®] 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE[®] technologies targeting synergistic, unmet medical needs.

==> picture [581 x 93] intentionally omitted <==

Attachment 1 – Ms Michele Dilizia – Key Terms and Conditions of Employment

Effective Date

30 September 2020

Term

Appointment on an on-going basis subject to termination by either party.

Fixed Remuneration

$230,000 per annum comprising base salary and superannuation.

Short/Long Term Incentives

Any short or long term incentives will be considered by the Company’s Nomination and Remuneration Committee, and will be announced to the market when any such incentive is put in place.

Termination and Notice

Ms Dilizia may terminate the Employment at any time and for any reason by giving to the Company 2 months’ notice in writing.

The Company may terminate the Employment at any time and for any reason by giving Ms Dilizia 6 months’ notice in writing.

==> picture [581 x 93] intentionally omitted <==